Holen Sie sich die Stockscreener-App
2.89
15.26%
0.40
Handel nachbörslich:
2.89
Schlusskurs vom Vortag:
$2.49
Offen:
$2.43
24-Stunden-Volumen:
5.80M
Relative Volume:
2.41
Marktkapitalisierung:
$264.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.741
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+23.71%
1M Leistung:
+55.98%
6M Leistung:
+146.35%
1J Leistung:
-32.47%
1-Tages-Spanne:
$2.36
$2.89
1-Wochen-Bereich:
$2.2301
$3.34
52-Wochen-Spanne:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.89 | 227.75M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025 - MarketScreener
Cabaletta Bio (CABA) Names Steve Gavel as Chief Commercial Officer - GuruFocus
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - MarketScreener
Cabaletta Bio Inc. stock chart pattern explainedEarnings Growth Summary & Entry Point Strategy Guides - newser.com
How Cabaletta Bio Inc. stock reacts to bond yields2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025July 2025 Summary & Community Verified Swing Trade Signals - newser.com
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning - MyChesCo
Cabaletta Bio (CABA): Assessing Valuation After RESET-PV Trial Results Spark Investor Interest - Yahoo Finance
Using flow based indicators on Cabaletta Bio Inc.July 2025 Closing Moves & Daily Momentum Trading Reports - newser.com
Measuring Cabaletta Bio Inc.’s beta against major indicesTrade Signal Summary & Daily Profit Focused Stock Screening - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com
What candlestick patterns are forming on Cabaletta Bio Inc.2025 Dividend Review & Verified Entry Point Signals - newser.com
Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Cabaletta Bio (CABA) Is Up 12.6% After CAR T Therapy Shows Early Success Without Preconditioning – Has the Bull Case Changed? - Yahoo Finance
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
Complete B‑cell depletion in 2 of 3 PV patients — Cabaletta rese‑cel 1x10^6 cells/kg without preconditioning - Stock Titan
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com
Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha
Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):